Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical is currently trading at Rs. 974.50, up by 13.35 points or 1.39% from its previous closing of Rs. 961.15 on the BSE.

The scrip opened at Rs. 954.90 and has touched a high and low of Rs. 976.00 and Rs. 944.00 respectively. So far 33,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1085.40 on 30-May-2013 and a 52 week low of Rs. 599.70 on 20-Jun-2012.

Last one week high and low of the scrip stood at Rs. 985.20 and Rs. 916.00 respectively. The current market cap of the company is Rs. 1, 00,914 crore.

The promoters holding in the company stood at 63.68% while Institutions and Non-Institutions held 26.00% and 10.32% respectively.

Pfizer Inc has reached a $2.15 billion settlement with Teva Pharmaceuticals Industries and Sun Pharmaceutical Industries related to patent infringement on its acid-reflux drug Protonix, which reduces the secretion of stomach acids and is used to treat the effects of gastroesophageal reflux disease.

As per the terms of settlement, Teva and Sun will compensate Pfizer's subsidiary Wyeth and Takeda for the damages suffered when two companies launched 'at-risk' generic versions of Protonix prior to the January 2011 expiration of the patent for pantoprazole, the drug's active ingredient.

While, Israel-based Teva will pay $800 million in 2013 and the remaining $800 million by October 2014. Sun Pharma will make its entire payment of $550 million in 2013. Out of the total amount received, Pfizer will receive 64% of the settlement and its partner Japan’s Takeda Pharmaceutical Co, will receive 36% or about $774 million from the settlement.